Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Porcine NPH insulin is an intermediate-acting form of animal-derived (pork) insulin complexed with protamine and zinc to prolong its action. It is used to treat patients with diabetes mellitus, particularly those who are unable to tolerate recombinant human insulins or whose diabetes cannot be adequately controlled by them. The mechanism of action involves replacing endogenous human insulin, thereby facilitating glucose uptake into cells and lowering blood glucose levels. Its onset of action occurs within 1–3 hours, peaks at 6–8 hours, and lasts up to 24 hours. Porcine NPH insulins were historically important before the widespread adoption of recombinant human insulins[1][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on porcine NPH insulin.